These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34628108)

  • 1. Challenges of evaluating and modelling vaccination in emerging infectious diseases.
    Madewell ZJ; Dean NE; Berlin JA; Coplan PM; Davis KJ; Struchiner CJ; Halloran ME
    Epidemics; 2021 Dec; 37():100506. PubMed ID: 34628108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine development for emerging infectious diseases.
    Excler JL; Saville M; Berkley S; Kim JH
    Nat Med; 2021 Apr; 27(4):591-600. PubMed ID: 33846611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats.
    Longini IM; Yang Y; Fleming TR; Muñoz-Fontela C; Wang R; Ellenberg SS; Qian G; Halloran ME; Nason M; Gruttola V; Mulangu S; Huang Y; Donnelly CA; Henao Restrepo AM
    Clin Trials; 2022 Dec; 19(6):647-654. PubMed ID: 35866633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccinomics: a future avenue for vaccine development against emerging pathogens.
    de la Fuente J; Contreras M
    Expert Rev Vaccines; 2021 Dec; 20(12):1561-1569. PubMed ID: 34582295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral Emerging Diseases: Challenges in Developing Vaccination Strategies.
    Trovato M; Sartorius R; D'Apice L; Manco R; De Berardinis P
    Front Immunol; 2020; 11():2130. PubMed ID: 33013898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping time use in clinical trials for vaccines against emerging infectious diseases.
    Mandi H; Yimer SA; Norheim G
    Clin Trials; 2021 Jun; 18(3):286-294. PubMed ID: 33653146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
    Voss G; Jacquet JM; Tornieporth N; Kampmann B; Karron R; Meulen AS; Chen R; Gruber M; Lurie N; Weller C; Cramer JP; Saville M; Darko M
    Vaccine; 2021 Dec; 39(51):7357-7362. PubMed ID: 34799142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
    Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
    Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Concepts and Technologies in Vaccine Development.
    Brisse M; Vrba SM; Kirk N; Liang Y; Ly H
    Front Immunol; 2020; 11():583077. PubMed ID: 33101309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study.
    Li R; Li Y; Zou Z; Liu Y; Li X; Zhuang G; Shen M; Zhang L
    Front Public Health; 2021; 9():801763. PubMed ID: 35083192
    [No Abstract]   [Full Text] [Related]  

  • 11. Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases.
    Xu Z; Ho M; Bordoloi D; Kudchodkar S; Khoshnejad M; Giron L; Zaidi F; Jeong M; Roberts CC; Park YK; Maslow J; Abdel-Mohsen M; Muthumani K
    Methods Mol Biol; 2022; 2410():229-263. PubMed ID: 34914050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.
    Billington J; Deschamps I; Erck SC; Gerberding JL; Hanon E; Ivol S; Shiver JW; Spencer JA; Van Hoof J
    Health Secur; 2020; 18(3):241-249. PubMed ID: 32348165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using cross-species vaccination approaches to counter emerging infectious diseases.
    Warimwe GM; Francis MJ; Bowden TA; Thumbi SM; Charleston B
    Nat Rev Immunol; 2021 Dec; 21(12):815-822. PubMed ID: 34140665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Funding vaccines for emerging infectious diseases.
    Wong G; Qiu X
    Hum Vaccin Immunother; 2018 Jul; 14(7):1760-1762. PubMed ID: 29194012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unprecedented pace and partnerships: the story of and lessons learned from one Ebola vaccine program.
    Gupta SB; Coller BA; Feinberg M
    Expert Rev Vaccines; 2018 Oct; 17(10):913-923. PubMed ID: 30269612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in managing COVID-19 from an emerging infectious disease to a common respiratory infectious disease: What are the subsequent impacts on and new challenges for healthcare systems?
    Karako K; Song P; Chen Y; Karako T
    Biosci Trends; 2022; 16(6):381-385. PubMed ID: 36567122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines for neglected, emerging and re-emerging diseases.
    Madhav A; Mehrotra T; Sinha P; Mutreja A
    Semin Immunol; 2020 Aug; 50():101423. PubMed ID: 33250352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.
    Oyarzun P; Kashyap M; Fica V; Salas-Burgos A; Gonzalez-Galarza FF; McCabe A; Jones AR; Middleton D; Kobe B
    Front Immunol; 2021; 12():598778. PubMed ID: 33717077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases.
    Maslow JN
    Hum Vaccin Immunother; 2019; 15(10):2230-2234. PubMed ID: 31644396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.